# PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

> **NCT06721689** · PHASE1,PHASE2 · RECRUITING · sponsor: **Theodore Laetsch** · enrollment: 59 (estimated)

## Conditions studied

- Refractory Solid Tumors
- Relapsed Solid Tumors
- Relapsed Neuroblastoma
- Refractory Neuroblastoma
- Relapsed Rhabdomyosarcoma
- Refractory Rhabdomyosarcoma

## Interventions

- **DRUG:** PEEL-224
- **DRUG:** Vincristine
- **DRUG:** Temozolomide (TMZ)

## Key facts

- **NCT ID:** NCT06721689
- **Lead sponsor:** Theodore Laetsch
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-23
- **Primary completion:** 2030-04
- **Final completion:** 2031-04
- **Target enrollment:** 59 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06721689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06721689, "PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06721689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*